Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review

Leukemia Research

Volumn 35, Issue 5, 2011, Pages 566-570

  Guariglia, Roberto ^a   Martorelli, Maria Carmen ^a   Villani, Oreste ^a   Pietrantuono, Giuseppe ^a   Mansueto, Giovanna ^a   D'Auria, Fiorella ^a   Grieco, Vitina ^a   Bianchino, Gabriella ^a   Lerose, Rosa ^a   Bochicchio, Giovanni Battista ^a   Musto, Pellegrino ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

Deferasirox; Hemopoietic improvement; Iron chelation; Myelodysplastic syndromes; Transfusion dependence

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DANAZOL; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; GLUTATHIONE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN;

ABSENCE OF SIDE EFFECTS; AGED; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME ANALYSIS; DRUG DOSE ESCALATION; ERYTHROCYTE TRANSFUSION; ERYTHROID CELL; FATIGUE; FERRITIN BLOOD LEVEL; HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IRON CHELATION; IRON OVERLOAD; KARYOTYPE; LEUKOCYTE COUNT; LIPID PEROXIDATION; MALE; MEGAKARYOCYTE; MONOSOMY; MORBIDITY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEUTROPHIL COUNT; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY THROMBOCYTOPENIA; REVIEW; RING CHROMOSOME; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; AGED; BENZOIC ACIDS; BLOOD TRANSFUSION; CHELATION THERAPY; HEMATOPOIESIS; HUMANS; IRON CHELATING AGENTS; MALE; MYELODYSPLASTIC SYNDROMES; TRIAZOLES; UP-REGULATION;

EID: 79954569782     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.11.027     Document Type: Review

References (39)

1. Brunning R.D., Orazi A., Germing U., Le Beau M.M., Porwit A., Bumann I., et al. Myelodysplastic syndromes/neoplasms, overview. World Health Organization classification of tumors of haematopoietic and lymphoid tissue 2008, 88-93. IARC Press, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, G. Thiele, J.W. Vardiman (Eds.).
2. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
3. Rose C., Brechignac S., Vassilief D., Pascal L., Stamatoullas A., Guerci A., et al. GFM (Groupe Francophone des Myélodysplasies): Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res 2010, 34:864-870.
4. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
5. Jabbour E., Kantarjian H.M., Koller C., Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 2008, 112:1089-1095.
6. Alessandrino E.P., Della Porta M.G., Bacigalupo A., Malcovati L., Angelucci E., Van Lint M.T., et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 2010, 95:476-484.
7. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
8. Brittenham G.M., Griffith P.M., Nienhuis A.W., McLaren C.E., Young N.S., Tucker E.E., et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994, 331:567-573.
9. Bennett J.M. Bennett JM; MDS Foundation's Working Group on Transfusional Iron Overload: Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008, 83:858-861.
10. Santini V., Alessandrino P.E., Angelucci E., Barosi G., Billio A., Di Maio M., et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res 2010, 34:1576-1588.
11. List A.F., Baer M.R., Steensma D.P., Raza A., Esposito J., Martinez-Lopez N., et al. Two-year analysis of efficacy and safety of Defeasirox (Exjade®) treatment in myelodysplastic syndrome patients enrolled in the US03 study. Blood 2009, 114:3829. (ASH Annual Meeting Abstracts).
12. Cappellini M.D., Porter J., El-Beshlawy A., Li C.K., Seymour J.F., Elalfy M., et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010, 95:557-566.
13. Badawi M.A., Vickars L.M., Chase J.M., Leitch H.A. Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. Adv Hematol 2010, 10.1155/2010/164045.
14. Leitch H.A., Vickars L.M. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?. Hematol Am Soc Hematol Educ Program 2009, 664-672.
15. Zurlo M.G., De Stefano P., Borgna-Pignatti C., Di Palma A., Piga A., Melevendi C., et al. Survival and causes of death in thalassaemia major. Lancet 1989, 2:27-30.
16. Schmid M. Iron chelation therapy in MDS: what have we learnt recently?. Blood Rev 2009, 23(Suppl. 1):S21-S25.
17. Schafer A.I., Cheron R.G., Dluhy R., Cooper B., Gleason R.E., Soeldner J.S., et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981, 304:319-324.
18. Prus E., Fibach E. Flow cytometry measurement of the labile iron pool in human hematopoietic cells. Cytometry A 2008, 73:22-27.
19. Hartmann J., Sinzig U., Wulf G., Truemper L.H., Braulke F., Konietscke F., et al. Evidence for a suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS. Blood 2008, 112:2694a. (ASH Annual Meeting Abstracts).
20. Chan L.S.A., Buckstein R., Reis M.D., Chesney A., Lam A., Cheung M.C., et al. Iron overload and haematopoiesis in MDS: does blood transfusion promote progression to AML?. Blood 2008, 112:2685a. (ASH Annual Meeting Abstracts).
21. Olivieri N.F., Nathan D.G., MacMillan J.H., Wayne A.S., Liu P.P., McGee A., et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994, 331:574-578.
22. Leitch H.A., Goodman T.A., Wong K.K., Vickars L.M., Galbraith P.F., Leger C.S. Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy. Blood 2006, 108:78a.
23. Jensen P.D., Heickendorff L., Pedersen B., Bendix-Hansen K., Jensen F.T., Christensen T., et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996, 94:288-299.
24. Messa E., Cilloni D., Messa F., Arruga F., Roetto A., Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008, 120:70-74.
25. Capalbo S., Spinosa G., Franzese M.G., Palumbo G. Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long term reduction in transfusion requirements. Acta Haematol 2009, 121:19-20.
26. Okabe H., Suzuki T., Omori T., MoriI M., Uehara E., Hatano K., et al. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome. Rinsho Ketsueki 2009, 50:1626-1629.
27. Oliva E.N., Ronco F., Marino A., Alati C., Praticò G., Nobile F. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion 2010, 50:1568-1570.
28. Molteni A., Riva M., Speziale V., Morra E., Cappellini M.D. Iron-chelation therapy in MDS/IMF patients: does it really impact on transfusion requirement?. Haematologica 2010, 95(s2):1410.
29. Nishiuchi T., Okutani Y., Fujita T., Yoshida K., Ohnishi H., Haba R. Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome. Int J Hematol 2010, 91:333-335.
30. Breccia M., Loglisci G., Salaroli A., Cannella L., Santopietro M., Alimena G. Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response. Acta Haematol 2010, 124:46-48.
31. Smeets M.E., Vreugdenhil G., Holdrinet R.S. Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol 1996, 51:243-244.
32. Di Tucci A.A., Murru R., Alberti D., Rabault B., Depilano S., Angelucci E. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol 2007, 78:540-542.
33. Park S.J., Han C.W. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci 2008, 23:320-323.
34. Marsh J.H., Hundert M., Schulman P. Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia. Br J Haematol 1990, 76:148-149.
35. Jensen P.D., Jensen I.M., Ellegaard J. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 1992, 80:121-124.
36. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. World Health Organization (WHO) international working group: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
37. Vreugdenhil G., Smeets M., Feelders R.A., Van Eijk H.G. Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia. Acta Haematol 1993, 89.
38. Ghoti H., Fibach E., Merkel D., Perez-Avraham G., Grisariu S., Rachmilewitz E.A. Changes in parameters of oxidative stress and free iron biomarkers during treatment with Deferasirox in iron-overloaded patients with Myelodysplastic syndromes. Haematologica 2010, 95:1433-1434.
39. Messa E., Carturan S., Maffè C., Pautasso M., Bracco E., Roetto A., et al. Deferasirox is a powerful NF-kB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from intracellular iron chelation and reactive oxygen species scavenging. Haematologica 2010, 95:1308-1316.